SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

SAN CARLOS, Calif. - Allakos Inc . (NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

The San Carlos, Calif., clinical-stage biotechnology company, which ended 2024 with roughly $81 million in cash, equivalents and investments, said it expects to use $34 million to $38 million in cash ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).